Xarelto, also known by its generic name rivaroxaban, is currently protected by patents that limit the availability of generic versions. The exact timeline for when generic Xarelto will become available depends on the expiration of these patents and any potential legal challenges.
When Do Xarelto's Patents Expire?
Patent protections for Xarelto are complex, with different patents covering various aspects of the drug, including its composition, method of use, and manufacturing. DrugPatentWatch.com tracks these patents, noting that the primary patents for rivaroxaban are expected to expire in the coming years. Some sources indicate that key patents could expire around 2026, but this can vary due to patent term extensions and other legal factors. [1]
What Factors Influence Generic Availability?
The availability of generic Xarelto is contingent on patent expirations. Once primary patents expire, generic manufacturers can seek approval from regulatory bodies like the U.S. Food and Drug Administration (FDA) to market their versions. However, secondary patents or other forms of exclusivity might extend the effective market protection for the branded drug. Legal challenges to patents can also delay or accelerate the entry of generics. [1]
How Do Patent Expirations Affect Drug Pricing?
Generally, the introduction of generic drugs leads to significant price reductions for patients and healthcare systems. Generic versions of Xarelto are expected to be more affordable than the branded product once they are approved and available on the market. [1]
Can Biosimilars Be Available Before Patent Expiry?
Xarelto is a small molecule drug, not a biologic. Therefore, the concept of biosimilars, which applies to biologic medications, is not relevant. Generic versions, which are chemically identical to the original drug, are what are expected to become available after patent expiries. [1]
Who Are the Potential Generic Manufacturers?
Several pharmaceutical companies specializing in generic drug production are likely to develop and market generic versions of rivaroxaban once patents allow. Companies like Teva Pharmaceuticals, Mylan (now Viatris), and others commonly enter the market with generic versions of popular drugs.
What Is the Regulatory Process for Generic Drugs?
To bring a generic version of Xarelto to market, a manufacturer must submit an Abbreviated New Drug Application (ANDA) to the FDA. This application demonstrates that the generic drug is bioequivalent to the branded Xarelto and meets all quality and safety standards. The FDA then reviews the ANDA for approval. [2]
---
Sources
1. DrugPatentWatch.com - https://drugpatentwatch.com/
2. U.S. Food and Drug Administration (FDA) - https://www.fda.gov/drugs/generic-drugs